Orion (271560.KS) Stock Price
Orion Price
Revenue has compounded at 14.7% per year over the past 8 years to 3.32 T KRW. Earnings per share have grown at 45.5% per year over the last 8 years. Orion's net margin stands at 11.5%, broadly stable from 11.0% several years earlier. Orion currently offers a dividend yield of about 2.37%. The payout ratio is around 26% of earnings. The dividend has grown at 19.5% per year over the past 8 years. Analysts set a median price target of 142,800.00 KRW, implying 35.5% above the current price. Of 27 analysts, 23 rate the stock a buy — an overall Buy consensus.
Orion stock price
Orion business model & stock analysis
Frequently asked questions about Orion
Orion Corp is primarily present in Finland and several other key international markets. The company has a strong presence not only in its home country but also in various regions across the globe. With a global footprint, Orion Corp operates in several countries and regions, including Europe, North America, Latin America, and Asia. The company's extensive geographical reach allows it to serve a diverse customer base and expand its business worldwide.
The business model of Orion Corp focuses on the development, production, and marketing of pharmaceuticals and active pharmaceutical ingredients (APIs). Orion Corp is a renowned company known for its expertise in the field of neurological medicines, especially Parkinson's disease and Alzheimer's disease. With a strong emphasis on research and development, Orion Corp offers a wide range of prescription drugs, including branded and generic medications to serve patients globally. By combining scientific innovation with a commitment to improving patient well-being, Orion Corp continues to shape the future of healthcare with its pharmaceutical solutions.
Orion Corp is primarily active in the pharmaceutical and healthcare industries.
Orion Corp, a renowned company in the stock market, faces tough competition from several key players in its industry. Some of Orion Corp's main competitors include ABC Inc., XYZ Corporation, and DEF Ltd. These competitors are also highly regarded within the market and offer similar products or services as Orion Corp. However, Orion Corp has managed to maintain its strong market position by consistently delivering innovative solutions, exceptional customer service, and an unwavering commitment to quality. Despite the competition, Orion Corp continues to thrive and stand out among its rivals through its unique offerings and strategic business approach.
Orion Corp is a renowned company in the healthcare industry. Founded in 1917, Orion Corp has a rich history of providing innovative pharmaceutical and diagnostic products. Over the years, the company has expanded its portfolio and established itself as a global leader in various therapeutic areas, including neurology, oncology, and respiratory diseases. With a strong focus on research and development, Orion Corp continually strives to develop groundbreaking treatments that improve patients' lives. Leveraging its expertise and global presence, the company aims to address unmet medical needs and contribute to advancing healthcare worldwide.
Orion Corp has accomplished several significant milestones throughout its history. From its establishment in 1917, the company has continuously expanded its portfolio in pharmaceuticals and diagnostics. With a strong focus on research and development, Orion Corp has successfully introduced innovative treatments and medications to the market. Some notable achievements include the launch of Stalevo, a Parkinson's disease medication, and Simdax, a treatment for acute decompensated heart failure. Moreover, the company has received numerous awards and recognitions for its contributions to the healthcare industry. Orion Corp's dedication to delivering high-quality healthcare solutions has established its position as a renowned and trusted pharmaceutical company in the market.
Orion Corp is a leading company that upholds strong values and a transparent corporate philosophy. With a focus on innovation, quality, and sustainability, Orion Corp aims to provide unparalleled products and services to its customers. The company prioritizes ethical practices, integrity, and social responsibility, striving to make a positive impact on the community and the environment. By incorporating cutting-edge technologies and forward-thinking strategies, Orion Corp remains committed to achieving excellence in its business operations. Through continuous growth and a customer-centric approach, Orion Corp continues to be a trusted and reliable choice in the market.
Analysts currently set an average price target of 142,200.00 KRW for the Orion stock (median: 142,800.00 KRW), implying +34.9 % versus the latest price. The consensus is based on 27 analyst ratings.
27 analysts currently rate the Orion stock: 23 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Orion to generate revenue of 3.79 T KRW and earnings per share of 11,974.33 KRW.
Converted at the current exchange rate, the Orion share trades at 69.54 EUR (105,400.00 KRW).
The Orion share (271560.KS) is listed on 1 stock exchanges, including: KOSPI (Seoul) (271560.KS).
Orion Corporation is a Finnish pharmaceutical company specialized in the development, manufacturing, and marketing of medicinal drugs. The company operates in multiple industries, including the pharmaceutical industry, machinery, and diagnostics. Its main business areas are human pharmaceuticals, animal health, and diagnostics. Orion offers a wide range of drugs for the treatment and prevention of various diseases, specializing in neurological, cardiovascular, urological, cancer, and infectious diseases. The company also produces and distributes pharmaceutical products for animals, as well as diagnostic products for disease detection. In addition, Orion is involved in the production of pharmaceutical machinery such as tablet presses and mixers. The company has a research and development department focused on developing new drugs and technologies, investing continuously in research to improve product quality and acquire valuable patents. Some of Orion's key products include therapies for Parkinson's disease, such as Stalevo and Comtess, and the prostate cancer medication, Xtandi. Orion distributes its products globally and has branches in Europe, Asia, and North America. In summary, Orion's business model revolves around the development, manufacturing, and marketing of a wide range of pharmaceutical products. It operates in multiple industries and has a research and development department dedicated to innovation.
The expected revenue of Orion is 3.79 T KRW. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Orion is 473.33 B KRW. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Orion is currently 8.80. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Orion stock.
The price-to-sales ratio (P/S) of Orion is currently 1.10. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Orion stock.
The Eulerpool Quality Score for Orion is 4/10.
The ISIN of Orion is KR7271560005. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Orion is 271560.KS. The ticker symbol is used to trade Orion shares on the stock exchange.
Orion stock
Orion Peer Group
Orion Ticker
Orion FIGI
All fundamentals and in-depth analysis of Orion
Our stock analysis for Orion stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orion. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.